Twist Bioscience stock price target lowered to $36 by TD Cowen

Published 04/08/2025, 19:28
Twist Bioscience stock price target lowered to $36 by TD Cowen

Investing.com - TD Cowen has lowered its price target on Twist Bioscience (NASDAQ:TWST) to $36.00 from $58.00 while maintaining a Buy rating on the stock. The company’s shares, which have declined 7.8% in the past week, are currently trading near their 52-week low of $27.12. According to InvestingPro analysis, the stock appears undervalued at current levels.

The firm cited Twist Bioscience’s narrowed fiscal year 2025 guidance, which now accounts for a step-down in Next-Generation Sequencing (NGS) revenue as a key customer transitions from clinical to commercial stage. Despite near-term challenges, InvestingPro data shows the company maintaining strong revenue growth of 25.3% over the last twelve months. Get access to 8 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report.

Despite the price target reduction, TD Cowen noted Twist delivered solid gross margin performance, beating estimates by 370 basis points, primarily driven by NGS outperformance.

The research firm reported that Twist’s synthetic biology (SynBio) revenues were lighter than expected in the fiscal third quarter, though still showing 20% year-over-year growth.

TD Cowen identified NGS as a key growth driver for Twist Bioscience through 2026, with minimal residual disease (MRD) applications expected to more significantly contribute to the company’s growth in the future.

In other recent news, Twist Bioscience reported a notable 18% increase in revenue for Q3 2025, reaching $96.1 million. Despite this growth, the company recorded an adjusted EBITDA loss of $8 million, though this marks an improvement from the previous fiscal year. In a related development, Evercore ISI adjusted its price target for Twist Bioscience from $50.00 to $46.00, maintaining an Outperform rating. The research firm cited strong performance in the next-generation sequencing segment and solid gross margins as positive indicators. These updates reflect recent developments surrounding Twist Bioscience.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.